IMPACT Therapeutics Inc is a China-based company primarily engaged in the research, development, and commercialization of pharmaceutical products. The Company is principally engaged in the research and development of synthetic lethality-based precision anti-cancer therapies. The Company's product pipeline is primarily composed of Senaparib, as well as novel antibody-drug conjugates (ADCs) and degrader candidates. The Company distributes its products within the domestic market and to overseas markets.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
30/09/26	HK$14.07	+1.01%	9,625,600
29/09/26	HK$13.93	+7.48%	8,188,200
28/09/26	HK$12.96	-4.00%	6,362,200
25/09/26	HK$13.50	-5.13%	435,400
24/09/26	HK$14.23	-6.07%	8,119,400

Delayed Quote Hong Kong S.E.

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

12.03CNY

Average target price

27.28CNY

Spread / Average Target

+126.79%

Consensus

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Hong Kong S.E. 12:08:27 30/09/2026 +04			5-day change	1st Jan Change
14.07 ^HKD	+1.01%		-12.83%	-

09-18	IMPACT Therapeutics And Pharmanovia Receive Positive CHMP Opinion For Senaparib As First-Line Maintenance Treatment Of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, And Primary Peritoneal Cancer	CI
09-18	Impact Therapeutics Gets Positive EMA Opinion for Ovarian Cancer Drug	MT

Market Cap	3.4B 3.97B 506M 446M 423M 381M 719M 48.56B 728M 5.06B 1.95B 24.83B 1.9B 1.86B 79.59B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	2.58B 3.02B 385M 339M 321M 290M 546M 36.89B 553M 3.84B 1.48B 18.86B 1.44B 1.41B 60.47B	EV / Sales 2026 *	9.75x	EV / Sales 2027 *	3.8x
Free-Float	53.09%	Yield 2026 *	-	Yield 2027 *	-

09-18	IMPACT Therapeutics And Pharmanovia Receive Positive CHMP Opinion For Senaparib As First-Line Maintenance Treatment Of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, And Primary Peritoneal Cancer	CI
09-18	Impact Therapeutics Gets Positive EMA Opinion for Ovarian Cancer Drug	MT
09-07	Impact Therapeutics Joins Shenzhen-and Shanghai-Hong Kong Stock Connect Programs	MT
09-03	Hong Kong Stocks Fall on Thursday, Amid Bond Selloff, Rate Fears; HUTCHMED Jumps 14%	MT
09-03	Impact Therapeutics CEO Boosts Shareholding	MT
08-31	IMPACT Therapeutics, Inc Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-24	IMPACT Therapeutics to Join Hang Seng Composite Index	MT
08-12	Impact Therapeutics Announces IMP2794 as A Preclinical Candidate, A Highly Kat6a-Specific PROTAC from Its Proprietary Targeted Protein Degradation Platform	CI
08-11	IMPACT Therapeutics, Inc. Provides Preliminary Consolidated Earnings Guidance for the Six Months Ended 30 June 2026	CI
07-31	IMPACT Therapeutics, Inc and Pharmanovia Enter Exclusive License Agreement For Senaparib In Europe, Middle East And North Africa, Australia And New Zealand	CI
07-28	IMPACT Therapeutics, Inc Announces IMP3201 As A Preclinical Candidate, A First-In-Class CEACAM5-Targeted Dual-Payload ADC	CI
07-27	Impact Therapeutics Nominates Preclinical Candidate for GI Cancers	MT
07-21	Impact Therapeutics Announces Clinical Data for Senaparib, IMP4297, and IMP1707 Accepted for Poster Presentation at 2026 ESMO Congress	CI

1 day	+1.01%
1 week	-12.83%
Current month	-2.70%
1 month	-9.87%
3 months	-61.97%

IMPACT Therapeutics, Inc Stock

Stocks

7630

CNE100007LG4

Biotechnology & Medical Research

Valuation: IMPACT Therapeutics, Inc

Chart: IMPACT Therapeutics, Inc

Latest news: IMPACT Therapeutics, Inc

Press Releases: IMPACT Therapeutics, Inc

Quotes and Performance

Price Extremes

Managers and Directors: IMPACT Therapeutics, Inc

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

1 week	12.5	15.53
1 month	10.7	20.56
Current year	10.31	47.98
1 year	10.31	47.98
3 years	10.31	47.98
5 years	10.31	47.98
10 years	10.31	47.98

Manager	Title	Age	Since
Sui Xiong Cai CEO	Chief Executive Officer	69	01/06/2014
Hui Jun Deng DFI	Director of Finance/CFO	51	01/05/2024
Yan Hua Xu CTO	Chief Tech/Sci/R&D Officer	44	01/01/2025

Director	Title	Age	Since
Ye Tian BRD	Director/Board Member	69	01/06/2014
Sui Xiong Cai BRD	Director/Board Member	69	01/06/2014
Ning Ma BRD	Director/Board Member	44	01/03/2025

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
IMPACT THERAPEUTICS, INC	+1.01%	-12.83%	-	-	501M
WUXI APPTEC CO., LTD.	+4.16%	-0.30%	+58.96%	+94.17%	71.53B
ARGENX SE	-0.19%	-1.01%	+38.55%	+83.85%	60.12B
LONZA GROUP AG	-1.51%	+2.20%	+10.66%	+35.15%	48.85B
IQVIA HOLDINGS INC.	-0.05%	-0.46%	+48.77%	+36.65%	44.28B
REVOLUTION MEDICINES, INC.	+0.38%	+6.43%	+345.54%	+641.55%	43.83B
BEONE MEDICINES AG	+0.18%	-0.58%	+9.95%	+103.45%	41.53B
CELLTRION, INC.	-0.67%	-0.45%	+4.47%	+46.37%	30.13B
WUXI BIOLOGICS (CAYMAN) INC.	+4.77%	+6.46%	+41.54%	+22.78%	27.98B
INSMED INCORPORATED	-1.29%	-5.53%	-19.42%	+352.04%	25.25B
Average	+0.72%	-0.94%	+59.89%	+157.33%	39.4B
Weighted average by Cap.	+0.85%	+0.61%	+65.00%	+148.55%

	2026 *	2027 *
Net sales	265M 310M 39.47M 34.76M 32.93M 29.73M 56.04M 3.78B 56.76M 394M 152M 1.93B 148M 145M 6.2B	630M 737M 93.87M 82.66M 78.32M 70.7M 133M 9B 135M 937M 361M 4.6B 352M 345M 14.75B
Net income	-	-
Net Debt	-816M -955M -122M -107M -102M -91.68M -173M -11.67B -175M -1.21B -468M -5.97B -457M -447M -19.13B	-1.01B -1.18B -150M -132M -125M -113M -213M -14.38B -216M -1.5B -576M -7.35B -563M -551M -23.56B